October 08, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
- PTK 0796 potentially the first broad-spectrum antibiotic given by once-daily infusion or tablet to treat infections caused by drug-resistant bacteria such as MRSA
- Oral form of PTK 0796 could offer a convenient way for patients to continue outpatient antibiotic treatment after leaving hospital
- New antibiotics needed in fight against bacterial resistance, with an estimated 150,000 deaths a year from hospital-acquired infections across US[1] and EU[2]
- Novartis to make upfront payment to Paratek Pharmaceuticals; Paratek eligible for milestones and royalties on future sales
October 06, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine
- 27 million doses shipped to US market by Novartis - providing more seasonal flu vaccine earlier than in any previous year
- Shipments completed ahead of normal seasonal vaccine delivery schedules to allow for earlier vaccination
- First shipments of A(H1N1) vaccine delivered to US government less than four months after the pandemic declaration by the WHO
- A/Brisbane/59/2007, IVR-148 (H1N1)
- A/Uruguay/716/2007, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like virus)
- B/Brisbane/60/2008[2]
- Children between 6 months and 18 years of age
- Pregnant women
- People 50 years of age and older
- People of any age with certain chronic health conditions, such as asthma, diabetes or heart disease
- People in nursing homes and other long-term care facilities,
- Household contacts of person at high risk for complications from influenza,
- Household contacts and out-of-home caregivers of children less than 6 months of age
- Healthcare workers[9]
October 05, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Sandoz launches somatropin, the first-ever Japanese biosimilar, increasing access to key medicines in second largest global market
- Human growth hormone somatropin launch follows precedent-setting approval in June
- Paves way for entry of biosimilars in Japan, increasing access to affordable, high-quality biopharmaceuticals in world's second largest pharmaceuticals market
- European data indicates that biosimilars can save payors billions of dollars
September 30, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
- FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1]
- Results build on Phase III TRANSFORMS one-year study showing FTY720 reduced relapses significantly more than interferon beta-1a, a standard of care[2]
- Phase III efficacy and safety data confirm positive benefit-risk profile for lower 0.5 mg dose[1] and support planned submissions in US and EU at end of 2009
- Future development of FTY720 in relapsing forms of MS to focus on lower 0.5 mg dose
September 25, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis bronchodilator QAB149 recommended for approval in European Union to treat patients with chronic obstructive pulmonary disease
- QAB149 is set to become the first COPD therapy in the EU that combines 24-hour bronchodilation[1],[2] from a once-daily dose with onset of action within five minutes[3]
- A Phase III study vs. tiotropium showed significant lung function benefit[1], improvements in COPD symptoms[4] and significantly more days free of 'relief' medication use[5]
- COPD affects 210 million people globally[6], up to 82 million in Europe[7],[8], and is projected to become the third leading cause of death worldwide[9]
September 25, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis A(H1N1) Pandemic Influenza vaccine Focetria® receives positive opinion from CHMP
- Significant milestone in bringing pandemic influenza vaccines to market in Europe
- Novartis delivers first shipments of A(H1N1) vaccine to governments in Europe just three months after the WHO declaration of the pandemic
- Focetria formulated with MF59® adjuvant which can boost the body's immune response and increase protective antibody levels with less antigen than needed with non-adjuvanted vaccines
September 24, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines
- Acquisition of EBEWE Pharma provides strong platform for future growth of differentiated generics business
- New global center of excellence for injectable cancer medicines broadens portfolio of affordable medicines for patients
- Sandoz to focus on quick and seamless integration for customers and employees
September 17, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
- Valturna combines in a single pill valsartan, an angiotensin receptor blocker, with aliskiren, the only approved direct renin inhibitor
- Valturna is the first therapy to target two points within the renin angiotensin aldosterone system (RAAS), which plays a key role in regulating blood pressure
- Valturna offers significantly greater blood pressure reduction than either valsartan or aliskiren alone[1]
September 15, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis investigational bronchodilator QAB149 improves lung function and reduces breathlessness compared to tiotropium in patients with COPD
- New data show a higher proportion of patients treated with QAB149 achieved clinically relevant improvements in symptoms of breathlessness compared to tiotropium[1]
- Patients taking QAB149 experienced 20 percent more days free of 'relief' medication, used to treat acute episodes of severe breathlessness, compared to tiotropium[2]
- The Phase III data reinforce that once-daily QAB149 combines relevant 24-hour bronchodilation[3],[4] with an onset of action within five minutes[5]
September 03, 2009
![](https://webarchive.library.unt.edu/web/20091012031040im_/http://www.novartis.com/images/_common/plus.gif)
Novartis MF59® adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials
- First pilot trial of investigational A(H1N1) vaccine with 100 subjects indicates strong, potentially protective, immune response in 80% of subjects after one dose, more than 90% after two doses.
- MF59® adjuvanted cell culture-based A(H1N1) vaccine was well tolerated, pain at the injection site the most frequent adverse event.
- Larger pivotal trials with both cell culture and traditional egg based vaccines under way to include more than 6000 adults and children.